Compare RGCO & CERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RGCO | CERS |
|---|---|---|
| Founded | 1912 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | EDP Services |
| Sector | Utilities | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 232.9M | 276.0M |
| IPO Year | N/A | 1997 |
| Metric | RGCO | CERS |
|---|---|---|
| Price | $22.50 | $1.92 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | 8.8K | ★ 1.4M |
| Earning Date | 11-19-2025 | 11-06-2025 |
| Dividend Yield | ★ 3.62% | N/A |
| EPS Growth | ★ 11.26 | N/A |
| EPS | ★ 1.29 | N/A |
| Revenue | $95,334,212.00 | ★ $199,191,000.00 |
| Revenue This Year | $9.00 | $25.31 |
| Revenue Next Year | $8.30 | $9.50 |
| P/E Ratio | $17.78 | ★ N/A |
| Revenue Growth | 12.63 | ★ 13.03 |
| 52 Week Low | $19.06 | $1.12 |
| 52 Week High | $23.82 | $2.24 |
| Indicator | RGCO | CERS |
|---|---|---|
| Relative Strength Index (RSI) | 57.28 | 58.88 |
| Support Level | $21.86 | $1.81 |
| Resistance Level | $22.42 | $2.14 |
| Average True Range (ATR) | 0.59 | 0.13 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 75.37 | 62.70 |
RGC Resources Inc is involved in the business of distribution and sale of natural gas to residential, commercial, and industrial customers within its service territory in Roanoke, Virginia, and its surrounding localities. The company also provides certain non-regulated services. The company relies on multiple interstate pipelines to transport natural gas. The company operates in three segments: Gas Utility, which is the key revenue generator; Investment in Affiliates this segment reflects the income generated through the activities of the Company's investment in MVP and Southgate projects and Parent & Other including the unregulated activities of the Company as well as certain corporate eliminations.
Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety and generates revenue from the same.